Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease

Abstract

Purpose: To report an experience using directional atherectomy (DA) with antirestenotic therapy (DAART) in the form of drug-coated balloon (DCB) angioplasty vs DCB angioplasty alone in common femoral artery (CFA) occlusive lesions. Methods: A retrospective review was conducted of 47 consecutive patients (mean age 71 years; 26 men) treated between October 2011 and July 2016 using either DCB angioplasty alone (n=26) or DAART (n=21) for CFA lesions. The majority of patients had lifestyle-limiting claudication (14 DCB and 15 DAART). Mean lesion length (39±14 mm DCB and 34±16 mm DAART) and vessel calcification (17/26 DCB and 11/21 DAART) were comparable between the groups. There were 4 chronic total occlusions, all in the DAART group. The main outcome measure was primary patency. Key secondary outcomes were technical success, secondary patency, and freedom from clinically-driven target lesion revascularization (TLR). Results: Technical success rates were 89% following DCB angioplasty and 95% for DAART (p=0.41). The 88% 12-month primary patency and 89% freedom from TLR for DAART were higher than the 68% and 75% estimates following DCB angioplasty alone, but neither difference was statistically significant. However, the secondary patency estimate at 12 months was significantly higher in the DAART group (100% vs 81% for DCB, p=0.03). Bailout stenting (1 DCB vs 1 DAART), vessel perforation (1 DCB vs 0 DAART), access site complications (4 DCB vs 3 DAART), and distal embolization (0 DCB vs 1 DAART) were comparable, whereas DCB angioplasty had more non-flow-limiting dissections (8 vs 1 for DAART, p=0.02). Conclusion: Preparation of the atherosclerotic CFA with directional atherectomy was not associated with statistically significantly higher primary patency or freedom from TLR compared to DCB angioplasty alone at 12 months. Nonetheless, both modalities had promising outcomes in a primarily surgically treated vascular territory.

Keywords

antirestenotic therapy atherectomy common femoral artery drug-coated balloon drug-eluting balloon paclitaxel peripheral artery disease stenosis target lesion revascularization

Get full access to this article

View all access options for this article.

References

Ballotta

Gruppo

Mazzalai

et al . Common femoral artery endarterectomy for occlusive disease: an 8-year single-center prospective study. Surgery. 2010;147:268–274.

Malgor

Ricotta

2nd Bower

et al . Common femoral artery endarterectomy for lower-extremity ischemia: evaluating the need for additional distal limb revascularization. Ann Vasc Surg. 2012;26:946–956.

Kang

Patel

Conrad

et al . Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008;48:872–877.

Nishibe

Maruno

Iwahori

et al . The role of common femoral artery endarterectomy in the endovascular era. Ann Vasc Surg. 2015;29:1501–1507.

Siracuse

Gill

Schneider

et al . Assessing the perioperative safety of common femoral endarterectomy in the endovascular era. Vasc Endovascular Surg. 2014;48:27–33.

Nguyen

Amdur

Abugideiri

et al . Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015;61:1489–1494.

Bonvini

Rastan

Sixt

et al . Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011;58:792–798.

Bath

Avgerinos

A pooled analysis of common femoral and profunda femoris endovascular interventions. Vascular. 2016;24:404–413.

Baumann

Ruch

Willenberg

et al . Endovascular treatment of common femoral artery obstructions. J Vasc Surg. 2011;53:1000–1996.

10.

Katsanos

Spiliopoulos

Paraskevopoulos

et al . Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23:356–370.

11.

Cortese

Granada

Scheller

et al . Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37:1096–1103.

12.

Zeller

Langhoff

Rocha-Singh

et al ; DEFINITIVE AR Investigators. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017;10:e004848.

13.

Sixt

Cancino

Treszl

et al . Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58:682–686.

14.

Cioppa

Stabile

Popusoi

et al . Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–223.

15.

Stavroulakis

Schwindt

Torsello

et al . Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;24:181–188.

16.

Roberts

Niazi

Miller

et al . Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca++ trial. Catheter Cardiovasc Interv. 2014;84:236–244.

17.

Cioppa

Stabile

Salemme

et al . Combined use of directional atherectomy and drug-coated balloon for the endovascular treatment of common femoral artery disease: immediate and one-year outcomes. EuroIntervention. 2017;12:1789–1794.

18.

Tellez

Dattilo

Mustapha

et al . Biological effect of orbital atherectomy and adjunctive paclitaxel-coated balloon therapy on vascular healing and drug retention: early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis. EuroIntervention. 2014;10:1002–1008.

19.

Herisson

Heymann

Chétiveaux

et al . Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis. 2011;216:348–354.

20.

Tepe

Beschorner

Ruether

et al . Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther. 2015;22:727–733.

21.

Dattilo

Tsai

Kevin Rogers

et al . Acute and medium-term outcomes of endovascular therapy of obstructive disease of diverse etiology of the common femoral artery. Catheter Cardiovasc Interv. 2013;81:1013–1022.

22.

Paris

White

Collins

et al . Catheter-based therapy of common femoral artery atherosclerotic disease. Vasc Med. 2011;16:109–112.

23.

Soga

Tomoi

Sato

et al . Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease. Cardiovasc Interv Ther. 2013;28:250–257.

24.

Siracuse

Van Orden

Kalish

et al . Endovascular treatment of the common femoral artery in the Vascular Quality Initiative. J Vasc Surg. 2017;65:1039–1046.

25.

Mehta

Zhou

Paty

et al . Percutaneous common femoral artery interventions using angioplasty, atherectomy, and stenting. J Vasc Surg. 2016;64:369–379.

26.

Azéma

Davaine

Guyomarch

et al . Endovascular repair of common femoral artery and concomitant arterial lesions. Eur J Vasc Endovasc Surg. 2011;41:787–793.

27.

Thiney

Millon

Boudjelit

et al . Angioplasty of the common femoral artery and its bifurcation. Ann Vasc Surg. 2015;29:960–967.

28.

Linni

Ugurluoglu

Hitzl

et al . Bioabsorbable stent implantation vs.common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014;21:493–502.

29.

Gouëffic

Della Schiava

Thaveau

et al . Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv. 2017;10:1344–1354.